Menveo® Meningitis Vaccine Indicated for People 2 Months Through 55 Years of Age Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Preservative Free 10 mcg - 5 mcg / 0.5 mL Injection Single-Dose Vial 0.5 m
Exam Shorts MediShorts® Small / Medium Navy Blue Nonwoven Adult Disposable
Menveo® Meningitis Vaccine Indicated for People 2 Months Through 55 Years of Age Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Con
and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Strength
Preservative Free
Type
58160095509
UNSPSC Code
SLI Medical Acceptable Dating: we will ship >= 90 days
User
Requires Refrigeration
Volume
10 mcg - 5 mcg / 0.5 mL
Intramuscular
51201610
Indicated for People 2 Months Through 55 Years of Age
0.5 mL
Features
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A
C
Y
and W-135. MENVEO is approved for use in persons 2 months through 55 years of age
MENVEO is supplied in two vials that must be combined prior to administration: reconstitute the MenA lyophilized conjugate vaccine component with the MenCYW-135 liquid conjugate vaccine component immediately before administration
Menveo® Meningitis Vaccine Indicated for People 2 Months Through 55 Years of Age Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Con
